Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug

The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.

source https://www.nytimes.com/2024/06/10/health/alzheimers-treatment-donanemab.html